fertility preservation after the
play

Fertility Preservation After the Over 70% express a desire for - PowerPoint PPT Presentation

Desire of Future Parenthood is Significant Fertility Preservation After the Over 70% express a desire for future offspring Diagnosis of Cancer Over 70% are concerned about the possibility of becoming infertile Mitchell Rosen, MD, HCLD


  1. Desire of Future Parenthood is Significant Fertility Preservation After the • Over 70% express a desire for future offspring Diagnosis of Cancer • Over 70% are concerned about the possibility of becoming infertile Mitchell Rosen, MD, HCLD Director, UCSF Fertility Preservation Program • Almost 1/3 report that infertility concerns and Reproductive Laboratories Program influenced their treatment decisions Partridge et al, J Clin Oncol. 2004 Preview Counseling Benefits Survivors • Fertility preservation – benefits as a survivor • Questions: – Counseled About Risk by Oncology Team? • Treatment effects – previously underestimated – Visited Fertility Specialist? • Options for preserving fertility- considerations – Preserved Fertility? • Survivors- options Letourneau, 2012 1

  2. Counseling Benefits Survivors Less Regret with Counseling Mean DRS Score • Measures: Yes No P-Value – Regret Counseled 10.8 12.6 About Risk by +/- 5.0 +/- 5.4 P<0.001 Oncology (n=499) (n=278) Team? – QOL Visited 8.5 11.6 Fertility +/- 5.2 +/- 4.5 P<0.001 Specialist? (n=42) (n=726) – SWLS 6.5 11.6 Preserved +/- 3.1 +/- 4.2 P<0.001 Fertility? (n=31) (n= 736) ����������������������� Letourneau, 2012 CCR/UCSF Study on Psychosocial Outcomes • Measures: – Regret score – QOL – SWLS Letourneau, 2012 2

  3. Reproductive Impairment-Chemotherapy Risk of Infertility only after Cancer Treatment Age �������������������������� Early Cancer Type Acute Ovarian Infertile but M enopause Failure Menstruating Type of cancer Ovarian reserve Leukemia 3% 30% 9% HD 8% 33% 9% NHL 10% 26% 20% Breast 13% 61% 28% GI 7% 53% 13% Genetics ������������������������������ Reproductive Impairment- Reproductive Impairment- Chemotherapy only Chemotherapy only Letourneau et al., Cancer 2011 Letourneau et al., Cancer 2011 3

  4. Assessment of Ovarian reserve: AFC � ��������� • 26 yo G0 � ������������� – Breast cancer � ��� – HR- � ��� ����!"����� – Stage 1 disease � #���������� – Oncotype-26 � $�% – ACT � ���������������� – Ovarian failure ������� Letourneau et al., Nature Oncology 2010 Ovarian Reserve and Reproductive Risks of infertility after Treatment? Impairment Anticipate fertility window will be reduced in all patients receiving cytotoxic therapy $�!����������� 4

  5. Options for Women Options for Fertility Preservation ��������������������� �������������� ����������������������� �������� �������� ����� !��"�����#��������� �������������� ��������������������� ������ $�%&�������'��������������������� ������ %���������������������()��������)�����* ����� +�������)��������� ����� !��"������������������ ����� �������������������� ����� ��������� (����������������������������������������* ����� ,�������� ����� Embryo/Egg Cryopreservation Ovarian Physiology • Established treatment • Takes 2-6 weeks** Ovulation – Ovarian stimulation, egg retrieval Antral follicle Delay treatment 1 14 28 Cycle Days 5

  6. Ovarian Physiology Ovarian Physiology �"� ���&�'���������"���� Ovulation Ovulation Antral follicle Antral follicle atresia Preovulatory follicles 1 1 14 28 14 28 Cycle Days Cycle Days Ovarian Physiology Ovarian Stimulation 1.Conventional estrogen FSH Ovulation Ovulation Progesterone Antral follicle Antral follicle atresia atresia Preovulatory follicles Preovulatory follicles 1 1 14 28 14 28 Cycle Days Cycle Days 6

  7. Ovarian Stimulation Random Start = Conventional 1.Conventional Conventional Late Follicular Luteal P value 2. Random stimulation Start Phase Start Phase Start (n=88; 103 (n=12; 12 (n=21; 21 cycles) cycles) cycles) Age (yrs) 33.8 ± 5.3 33.3 ± 3.9 34.5 ± 5.1 NS Ovulation Antral follicle count (AFC) 13 (9-19) 11 (5.5-21) 13 (7-18.5) NS Days of ovarian stimulation 9 (8-10) 11 (10-11.5)a 11 (10-12)a <0.001 Total dose of gonadotropins (IU) 3405 ± 1127 3837 ± 1074 4208 ± 1462b 0.014 Gonadotropin dose/day 361 ± 94 366 ± 88 369 ± 87 NS Follicles � 13 mm 12 (6-17) 11.5 (7.5-18.5) 13 (9-19.5) NS Oocytes retrieved NS 15 (9-23) 14 (8.5-27) 16 (10.5-25) Mature oocytes (MII) retrieved 11 (6-16) NS 10.5 (5-16.5) 11 (6-18) MII oocyte / total oocytes Antral follicle ratio NS 0.71 (0.60-0.82) 0.74 (0.59-.80) 0.69 (0.56-.84) Oocyte / AFC ratio NS 1.14 (0.75-1.71) 1.27 (0.92-.73) 1.20 (0.92-.67) Mature oocyte / AFC ratio NS atresia Preovulatory follicles 0.83 (0.46-1.12) 0.84 (0.6-1.3) 0.83 (0.62-.22) Fert. rate after ICSI (2PN/MII) NS 0.83 (0.69-0.91) 0.78 (0.75-.80) 0.96 (0.77-1.0) ��(��(�����) 1 14 28 Cycle Days The PROMISE trial Other considerations…. randomized trial: Triptorelin vs. Placebo • Hormone receptors �������������������- – Modifications ( i.e aromatase inhibitors) !������������������ • Ovarian reserve, desires %������- – Multiple cycles )�����������������-��./01 )������������2������������34/01 – Hormone treatment- delays in building a family ���������-�561 (0.1)!�6/0�����71�89:/::5* • Genetic Risks( i.e BRCA) +�����������- – PGD for prevention of vertical transmission ��������� ������#���������(��������������* *��������������� 7

  8. Ovarian Tissue freezing Post- Treatment Options • Fertility preservation • 20-30 live births – (All Orthotopic transplant) • Infertility therapy +�� • Donor Eggs & Embryos • Challenges/Limitations • Surrogacy – Risk for recurrences – Short life (3-5 yrs) • Adoption • ischemia – General anesthesia Conclusion “ Parenting is unlike anything else I have ever • Fertility preservation – benefits as a survivor experienced. It is the most profoundly life-affirming thing I have ever done. • Treatment effects – previously underestimated I am grateful that -- through all the uncertainty and fear surrounding my cancer diagnosis and • Options for preserving fertility- considerations treatment -- we held on to that dream of becoming parents and made it a reality. ” • Survivors- options 8

  9. Thank You Clinical Team Research Team Marcelle Cedars MD Thom Remble UCSF Fertility Evelyn Mok-Lin MD Hakan Cakmak MD James Smith MD(male) Tomoko Ozawa PHD Preservation Jo Chien MD Eve Harris- Patient Navigator Michelle Melisko MD Program Audra Katz, RN Joe Letourneau MD Cathy Chin, RN Jessica Chan, MD Nanette Lerma, RN Erin Ebbel MD Xinli Yang-embryologist Sai Chan MS Rosemary Benson-Call Center Danielle Cipres MS Meera Shah MD 9

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend